WHO Launches First Global Database Tracking STI Rates

Originally surfaced July 6, 2026, drawing on a July 3 World Health Organization announcement about the launch of the WHO STI Prevalence Atlas.

WHO has launched what it calls the first global platform for consolidated, standardized STI prevalence data. The new STI Prevalence Atlas focuses on low- and middle-income countries and pulls together published and unpublished evidence collected from 2010 onward.

That is useful, but the key point is what the atlas is and is not. It is a data infrastructure launch. It is not a new diagnosis tool, not a personal risk calculator, and not a change in screening recommendations.

What WHO added

WHO says the database currently focuses on five infections: chlamydia, gonorrhoea, herpes simplex virus type 2, syphilis, and trichomoniasis. As of June 2026, the atlas includes data from 766 studies and 2,453 prevalence data points.

The atlas page says included studies must report clearly defined population groups with sufficient methodological detail. Most samples must have been collected in 2010 or later, and the sample size must be at least 100. The included evidence spans household surveys, studies in pregnant women, adolescents, key populations, sex workers, STI clinic attendees, baseline data from intervention studies, and case-control studies.

That breadth is the point. STI prevalence is not one number. It varies by country, population, study design, testing method, and time period. A single global headline can hide almost everything that matters for public-health planning.

Why this is not the same as updated global estimates

The atlas should not be read as WHO publishing a fresh global prevalence estimate for every STI. WHO describes it as an evolving database that can support country, regional, and global estimates over time.

That distinction matters. WHO separately publishes global and regional STI estimates, including its standing estimate of 374 million new infections with chlamydia, gonorrhoea, syphilis, or trichomoniasis among adults aged 15 to 49 in 2020. The new atlas is a source base for better evidence, not an instant replacement for every existing estimate.

Where lab testing fits

For LabTestSuperstore readers, the practical takeaway is modest: better surveillance data helps researchers and public-health programs understand STI burden, but individual testing still depends on the specific infection, exposure context, symptoms, and clinical situation.

LabTestSuperstore has background pages for several infection categories included in the WHO atlas, including the Basic STD Panel, Expanded STD Panel, chlamydia and gonorrhea test, syphilis test, herpes test, and trichomoniasis test. These pages explain what each test covers. They do not replace clinical care or public-health guidance.

The atlas also has one limitation that matters in the United States: WHO says the current dashboard focuses on low- and middle-income countries. It is still relevant for global evidence, but it should not be treated as a direct map of current U.S. prevalence.

What to watch next

The useful follow-up is whether researchers and health agencies use the atlas to improve future estimates, identify missing data, and make STI surveillance less fragmented. The database is designed to expand as new studies are published and reviewed, and WHO says additional infections may be added later.

For now, the launch is mainly a data-quality story. It gives public-health teams a more standardized place to look. It does not tell an individual person when to test, which test to order, whether they have an STI, or how often they need screening.

This article is editorial commentary and is not medical advice. It has not been reviewed by a physician and should not be used to make decisions about diagnosis, STI treatment, partner notification, prevention medication, or testing frequency.